Showing results (141-150 of 437) with videos related to
Sort By:
Pageof 44
Expert Review of Hematology|January 30, 2014
Current strategies for treatment of relapsed/refractory multiple myelomaJacob P Laubach, Peter M Voorhees, Hani Hassoun, et al.Leukemia & Lymphoma|March 15, 2022
Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparisonKatja Weisel, Ajay K Nooka, Evangelos Terpos, et al.Pharmacological Research|November 26, 2016
Deacetylase inhibitors as a novel modality in the treatment of multiple myelomaPaul G Richardson, Philippe Moreau, Jacob P Laubach, et al.Expert Review of Hematology|September 9, 2017
Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agentPaul Richardson, Anuja Roy, Suddhasatta Acharyya, et al.Cancer Research|May 19, 2007
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cellsXiangguo Liu, Ping Yue, Shuzhen Chen, et al.Cancer Research|May 19, 2007
The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cellsYuanzheng Qiu, Xiangguo Liu, Wei Zou, et al.The Journal of Biological Chemistry|March 26, 2010
Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradationChunyang Li, Shuzhen Chen, Ping Yue, et al.Cancer|August 25, 2023
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trialAjay K Nooka, Adam D Cohen, Hans C Lee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2022
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With MyelomaAjay K Nooka, Uma Shanmugasundaram, Narayana Cheedarla, et al.Blood|December 18, 2024
Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesisRemya Nair, An H Vu, Abigail K Freer, et al.Pageof 44